Use NeuraLight to track progression
- Trial ID
- NCT05862649
- Official Title
- A Multicenter Longitudinal Study to Evaluate the Correlation Between Oculometric Measures and Clinical Assessment in Patients With Idiopathic Parkinson's Disease (PALOMA Trial)
- Goal
- Use NeuraLight to track progression
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- NeuraLight
- Study Type
- INTERVENTIONAL
- Enrollment
- 300 participants
- Conditions
- Parkinson Disease
- Interventions
- NeuraLight
Plain-Language Summary
PALOMA aims to see whether precise eye movement measurements can track Parkinson's signs and line up with standard clinical assessments, offering a quick, objective way to monitor early PD. It uses NeuraLight, a noninvasive device that records oculometric measures like saccades, fixations, and blink patterns while you sit calmly, then compares those digital markers to clinicians' ratings without changing your Parkinson's medications. The trial is looking for 300 adults aged 40 to 85 with idiopathic PD diagnosed within five years, Hoehn and Yahr stage 1 to 2, normal or corrected vision, stable PD treatment, and no epilepsy, other neurologic diseases, recent substance abuse, inability to sit for 40 minutes, or pregnancy.
Locations
- Rush University, Chicago, Illinois, United States
- AIBILI research center, Coimbra, Portugal
- Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain
- University Hospital Zürich, Zurich, Switzerland
- The VCTC, Oxford, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying NeuraLight. PALOMA aims to see whether precise eye movement measurements can track Parkinson's signs and line up with standard clinical assessments, offering a quick, objective way to monitor early PD. It uses NeuraLight, a noninvasive device that records oculometric measures like saccades, fixations, and blink patterns while you sit calmly, then compares those digital markers to clinicians' ratings without changing your Parkinson's medications. The trial is looking for 300 adults aged 40 to 85 with idiopathic PD diagnosed within five years, Hoehn and Yahr stage 1 to 2, normal or corrected vision, stable PD treatment, and no epilepsy, other neurologic diseases, recent substance abuse, inability to sit for 40 minutes, or pregnancy.
- Who can participate?
- Participants must be between 40 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 5 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 3 months.